The University of Texas Health Science Center at San Antonio, also called UT Health San Antonio, is a leading academic health center with a mission to make lives better through excellence in advanced academics, life-saving research and comprehensive clinical care including health, dental and cancer services.
A specialist in both breast cancer and malignancies of the brain and spinal cord, Dr. Andrew Brennernot only focuses on clinical management, but also on the development of novel therapies to treat breast cancers and central nervous system tumors. A graduate of Texas A&M University, he earned his bachelors degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center - Science Park. His doctoral thesis focused on the role of the cyclin dependent kinase inhibitor p16INK4a in mammary tumorigenesis and immortilization. Dr. Brenners current interests have transitioned from cell cycle to the effect of hypoxia on chemokines and escape from antiangiogenics and the role of obesity in promoting breast tumorigenesis. Dr. Brenner received his medical degree from the Texas Tech University Health ScienceCenter and completed a residency in internal medicine at Scott and White Hospital in Lubbock. He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.
Publications
Aksenov, A. V., Smirnov, A. N., Magedov, I. V., Reisenauer, M. R., Aksenov, N. A., Aksenova, I. V., Pendleton, A. L., Nguyen, G., Johnston, R. K., Rubin, M., De Carvalho, A., Kiss, R., Mathieu, V., Lefranc, F., Correa, J., Cavazos, D. A., Brenner, A. J., Bryan, B. A., Rogelj, S., Kornienko, A. & Frolova, L. V. Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates against Drug-Resistant Cancer Cells. J. Med. Chem. 12;58(5):2206-20 (2015). PMID: 25671501
Bowers, L. W., Brenner, A. J., Hursting, S. D., Tekmal, R. R. & deGraffenried, L. A. Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production. Breast Cancer Res. Treat. 149(1):49-57 (2014). PMID: 25476497; PMCID: PMC4409140
Bowers, L. W., Maximo, I. X., Brenner, A. J., Beeram, M., Hursting, S. D., Price, R. S., Tekmal, R. R., Jolly, C. A. & deGraffenried, L. A. NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions. Cancer Res. 74, 4446-4457 (2014). PMID: 25125682
"You never know until you begin the studies how a human being is going to react to a new therapy, and we have to be very careful about how we proceed on that."
- Dr. Andrew Brenner
Our Providers
210-450-1000
